Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Frazier Life Sciences Secures $1.3 Billion for Early-Stage Biotech Ventures

Frazier Life Sciences, a prominent venture capital firm based in Palo Alto, has successfully raised $1.3 billion for its twelfth venture fund, marking a significant milestone in the pharmaceutical investment landscape. This latest fund, which surpassed its predecessor by over $300 million, underscores the growing appetite for early-stage biotechnology investments and Frazier's continued leadership in the sector.

NoahAI News7/31/2025

AbbVie Eyes $1B Acquisition of Gilgamesh Pharmaceuticals, Bolstering Mental Health Pipeline

AbbVie, a pharmaceutical giant, is reportedly in talks to acquire Gilgamesh Pharmaceuticals, a biotech company specializing in mental health treatments, for approximately $1 billion. This potential deal comes on the heels of a collaboration agreement between the two companies last year and signifies AbbVie's continued focus on expanding its psychiatric drug portfolio.

NoahAI News7/31/2025

CVS Health Raises 2025 Forecast on Strong Pharmacy Performance and Insurance Improvements

CVS Health, a leading healthcare giant, has announced an upward revision of its 2025 financial forecast, citing robust performance in its pharmacy business and significant improvements in its insurance unit during the second quarter of this year. This positive momentum has caught the attention of Wall Street analysts and investors alike.

NoahAI News7/31/2025

Lilly's Mounjaro Shows Promising Cardiovascular Benefits in Head-to-Head Trial with Trulicity

Eli Lilly has unveiled phase 3 results demonstrating that its dual-action GIP/GLP-1 therapy Mounjaro (tirzepatide) is comparable to the company's GLP-1 drug Trulicity in reducing cardiovascular risks among patients with Type 2 diabetes and heart disease. The findings from the Surpass-CVOT study mark a significant milestone in the evolving landscape of diabetes and cardiovascular treatments.

NoahAI News7/31/2025

FDA Leadership Shakeup: Tidmarsh Takes Reins at CBER Amid Prasad's Sudden Departure

In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has appointed George Tidmarsh, M.D., Ph.D., as the acting director of the Center for Biologics Evaluation and Research (CBER) following the abrupt resignation of Vinay Prasad, M.D. This development comes just nine days after Tidmarsh assumed leadership of the Center for Drug Evaluation and Research (CDER), marking a significant shift in the agency's top ranks.

NoahAI News7/31/2025

Dexcom Announces Leadership Transition as CEO Kevin Sayer Steps Down

Dexcom, a leading manufacturer of continuous glucose monitors (CGMs), has announced a significant leadership change. Kevin Sayer, who has served as CEO for the past decade, will step down from his role, with current Chief Operating Officer Jake Leach set to take the helm.

NoahAI News7/31/2025

FDA Leadership Shakeup: Vinay Prasad's Departure Signals Potential Shift in Regulatory Approach

Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), has abruptly left his position after just three months, sending shockwaves through the pharmaceutical industry. The sudden departure has analysts speculating about the future direction of drug approvals, particularly in the realms of cell and gene therapies and rare diseases.

NoahAI News7/31/2025

GE HealthCare Reports Strong Q2 Results, Adjusts Tariff Impact Outlook

GE HealthCare, a leading medical imaging company, has reported robust second-quarter results for 2025, with revenue reaching $5 billion, marking a 3% increase year over year. The company has also revised its financial outlook, projecting reduced tariff expenses and maintaining healthy demand for capital equipment.

NoahAI News7/31/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Financial Pressures

The pharmaceutical and biotech sectors are experiencing a significant wave of workforce reductions as companies across the industry implement cost-cutting measures and strategic realignments. From major players like Bristol Myers Squibb and Novartis to smaller biotechs, the trend of layoffs and restructuring efforts is reshaping the landscape of drug development and commercialization.

NoahAI News7/31/2025

Madrigal Pharmaceuticals Expands MASH Portfolio with $2B+ CSPC Deal

Madrigal Pharmaceuticals has announced a significant partnership with China-based CSPC Pharmaceutical Group Limited, marking a major expansion of its metabolic dysfunction-associated steatohepatitis (MASH) portfolio. The deal, valued at potentially over $2 billion, centers around the development of SYH2086, an oral preclinical GLP-1 therapy.

NoahAI News7/31/2025

Senate Confirms Susan Monarez as CDC Director Amid Agency Restructuring

In a significant development for public health leadership, the U.S. Senate has confirmed Susan Monarez, Ph.D., as the new director of the Centers for Disease Control and Prevention (CDC). The confirmation, which passed along party lines with a 51-47 vote, marks a historic moment as Monarez becomes the first CDC director to be confirmed by the Senate under the CDC Leadership Accountability Act of 2023.

NoahAI News7/31/2025

Pharmaceutical Industry Roundup: Key Developments and Deals

Madrigal Pharmaceuticals has made a significant move into the GLP-1 market, securing global rights to an oral GLP-1 drug from Hong Kong-based CSPC Pharmaceutical Group. The deal involves an upfront payment of $120 million, with potential additional payments of up to $2 billion tied to development, regulatory, and commercial milestones.

NoahAI News7/31/2025

«1...4 5 6...67 »